Loading
Glypican-3 is a fetal liver protein that reappears in liver cancer, giving CAR-T and bispecifics a clean target. This dossier gathers the 1 product (0 approved), 1 trial, 1 pathway and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Glypican-3 is a heparan sulfate proteoglycan modulating Wnt and Hedgehog signalling.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Hepatocellular carcinoma | 70-80% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Phase 2 |
|---|---|
| T-cell engager 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 1/2 | Recruiting | A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1) | - |
No recorded escape route names this target.
This KEGG map shows how sugar-coated proteins on the cell surface and in the surrounding matrix (proteoglycans such as syndecans, glypicans, CD44 and decorin) catch growth factors and hand signals to receptors. It matters because these molecules set how loudly growth signals reach the tumour cell and how easily it invades.
Which nodes have drugs →No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Glypican-3" OR ABSTRACT:"Glypican-3" OR TITLE:"GPC3" OR ABSTRACT:"GPC3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Glypican-3, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/gpc3.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/gpc3.json. Licence CC BY-NC 4.0.